Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose

Cancer Research

Volumn 70, Issue 24, 2010, Pages 10213-10223

  Okuyama, Hiroaki ^a   Endo, Hiroko ^a   Akashika, Tamaki ^a   Kato, Kikuya ^a   Inoue, Masahiro ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LACTIC ACID; MYC PROTEIN; OXYGEN; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL; CANCER CELL CULTURE; CELL DEATH; CELL HYPOGLYCEMIA; CELL HYPOXIA; CELL PROTECTION; CELL STRAIN HCT116; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENERGY RESOURCE; FEMALE; FLOW CYTOMETRY; GLUCOSE DEFICIENCY; HUMAN; HUMAN CELL; HYPOGLYCEMIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUTRITION; OXYGEN CONSUMPTION; OXYGEN SUPPLY; POLYSOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT;

ANIMALS; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; GLUCOSE; HCT116 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MICE; NECROSIS; OXYGEN; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR CELLS, CULTURED;

EID: 78650324886     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2720     Document Type: Article

References (50)

1. Vaupel P. Prognostic potential of the pre-therapeutic tumor oxygenation status. Adv Exp Med Biol 2009;645:241-6.
2. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev 2003;3: 721-32.
3. 2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
4. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
5. Casciari JJ, Sotirchos SV, Sutherland RM. Variations in tumor cell growth rates and metabolism with oxygen concentration, glucose concentration, and extracellular pH. J Cell Physiol 1992;151:386-94.
6. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000;16:653-99.
7. Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 1992;257:212-4.
8. Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 2004;6: 241-9.
9. Shim H, Chun YS, Lewis BC, Dang CV. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci U S A 1998; 95:1511-6.
10. Feil R, Wagner J, Metzger D, Chambon P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun 1997;237:752-7.
11. Indra AK, Warot X, Brocard J, Bornert JM, Xiao JH, Chambon P, et al. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen- inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res 1999;27:4324-7.
12. Metzger D, Clifford J, Chiba H, Chambon P. Conditional sitespecific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. Proc Natl Acad Sci U S A 1995;92: 6991-5.
13. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res 2005;65:7259-66.
14. Okuyama H, Krishnamachary B, Zhou YF, Nagasawa H, Bosch-Marce M, Semenza GL. Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1. J Biol Chem 2006;281:15554-63.
15. Guppy M, Kong SE, Niu X, Busfield S, Klinken SP. Method for measuring a comprehensive energy budget in a proliferating cell system over multiple cell cycles. J Cell Physiol 1997;170:1-7.
16. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007;11:407-20.
17. Corn PG, Ricci MS, Scata KA, Arsham AM, Simon MC, Dicker DT, et al. Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Therapy 2005;4:1285-94.
18. Ciechanover A, DiGiuseppe JA, Bercovich B, Orian A, Richter JD, Schwartz AL, et al. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci U S A 1991;88:139-43.
19. Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 1999;18:717-26.
20. Sonveaux P, Vegran F, Schroeder T,, Wergin MC, Verrax J, Rabbani ZN, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008;118:3930-42.
21. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988;240:177-84.
22. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39.
23. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
24. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-7.
25. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, , et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002;297:102-4.
26. Shachaf CM, Felsher DW. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res 2005;65:4471-4.
27. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007;12:108-13.
28. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev 2008;8:51-6.
29. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004;23:1949-56.
30. Kaidi A, Williams AC, Paraskeva C. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 2007;9:210-7.
31. Hann SR, Eisenman RN. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol 1984;4:2486-97.
32. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation- dependent c-Myc protein degradation. Proc Natl Acad Sci U S A 2004;101:9085-90.
33. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004;23:2116-25.
34. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates Myc protein stability and activity. Mol Cell 2003;11:1177-88.
35. von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 2003;11:1189-200.
36. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 2007;9:765-74.
37. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-46.
38. Li Q, Kluz T, Sun H, Costa M. Mechanisms of c-myc degradation by nickel compounds and hypoxia. PLoS One 2009;4:e8531.
39. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999;19:1-11.
40. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive cmyc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991;6:1915-22.
41. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69: 119-28.
42. Grandori C, Wu KJ, Fernandez P, Ngouenet C, Grim J, Clurman BE, et al. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev 2003;17:1569-74.
43. Mougneau E, Lemieux L, Rassoulzadegan M, Cuzin F. Biological activities of v-myc and rearranged c-myc oncogenes in rat fibroblast cells in culture. Proc Natl Acad Sci U S A 1984;81:5758-62.
44. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 1999;3:565-77.
45. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995;146:3-15.
46. Noch E, Khalili K. Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol Ther 2009;8:1791-7.
47. Zamaraeva MV, Sabirov RZ, Maeno E, Ando-Akatsuka Y, Bessonova SV, Okada Y. Cells die with increased cytosolic ATP during apoptosis: a bioluminescence study with intracellular luciferase. Cell Death Differ 2005;12:1390-7.
48. Plomp PJ, Gordon PB, Meijer AJ, Hoyvik H, Seglen PO. Energy dependence of different steps in the autophagic-lysosomal pathway. J Biol Chem 1989;264:6699-704.
49. Medina MA. Glutamine and cancer. J Nutr 2001;131(9Suppl):2539S- 42S; discussion 50S-1S.
50. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007;178:93-105.